-
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld, P., Dimopoulos, M. A., Boccadoro, M., Quach, H., Ho, P. J., Beksac, M., Hulin, C., Antonioli, E., Leleu, X., Mangiacavalli, S., Perrot, A., Cavo, M., Belotti, A., Broijl, A., Gay, F., Mina, R., Nijhof, I. S., van de Donk, N. W. C. J., Katodritou, E., Schjesvold, F., & 23 others, 25 Jan 2024, In: New England journal of medicine. 390, 4, p. 301-313 13 p.Research output: Contribution to journal › Article › Academic › peer-review
-
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study
van de Donk, N. W. C. J., Minnema, M. C., van der Holt, B., Schjesvold, F., Wu, K. L., Broijl, A., Roeloffzen, W. W. H., Gadisseur, A., Pietrantuono, G., Pour, L., van der Velden, V. H. J., Lund, T., Offidani, M., Grasso, M., Giaccone, L., Razawy, W., Tacchetti, P., Mancuso, K., Silkjaer, T., Caers, J., & 8 others, 1 Oct 2023, In: The Lancet Oncology. 24, 10, p. 1119-1133 15 p.Research output: Contribution to journal › Article › Academic › peer-review
-
Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13
Groen, K., Schjesvold, F. H., van der Holt, B., Levin, M-D., Seefat, M. R., Hansson, M., Leys, M. B. L., Regelink, J. C., Waage, A., Szatkowski, D., Axelsson, P., Hieu Do, T., Svirskaite, A., van der Spek, E., Haukas, E., Knut-Bojanowska, D., Ypma, P. F., Blimark, C. H., Mellqvist, U-H., van de Donk, N. W. C. J., & 5 others, 30 Sept 2023, In: HemaSphere. 7, 9, p. E940Research output: Contribution to journal › Letter › Academic › peer-review
- All publications
